• Product NameWedelolactone
• Brief DescriptionInhibitors
• Purification99.42%
• Biological ActivityWedelolactone inhibits adipogenic differentiation through ERK pathway, may be a novel inhibitory effect on adipogenic differentiation in hAMSCs. 2. Wedelolactone is an anti-Y agent for breast and prostate carcinomas in vitro and in vivo targeting multiple cellular proteins including androgen receptors, 5-lipoxygenase and topoisomerase IIα. 3. Wedelolactone could significantly inhibit the activation of LX-2 cells, the underlying mechanisms of which included inducing Bcl-2 family involved apoptosis, up-regulating phosphorylated status of ERK and JNK expressions, and inhibiting nuclear factor-κB (NF-κB) mediated activity.
• Target NameNF-κB inhibitor
• CAS No. 524-12-9
• Calculated MW 314.3
• Formulation C16H10O7
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Others
  SMILES:COC1=CC(=C2C(=C1)OC(=O)C3=C2OC4=CC(=C(C=C43)O)O)O
  Pathways:NF-κb
  Receptor:NF-κB
  Boling pt:
  Melting pt:
  Solubility:Soluble in Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
  Appearance:Yellow powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Nehybov T, et al. Wedelolactone Acts as Proteasome Inhibitor in Breast Cancer Cells. Int J Mol Sci. 2017 Mar 29;18(4).

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting